Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Novo Nordisk A/S Common Stock
(NY:
NVO
)
39.94
+0.80 (+2.03%)
Delayed Quote
Updated: 11:02 AM EDT, Oct 30, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Novo Nordisk A/S Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
The $1 Trillion Race: Why Eli Lilly Is Leaving Novo Nordisk in the Dust
↗
April 15, 2026
And can Novo Nordisk catch up to its rival in the weight loss market?
Via
The Motley Fool
Could AbbVie Crash Lilly's Weight‑Loss Party?
↗
April 14, 2026
AbbVie is making progress in this market, but it is still far behind the leader.
Via
The Motley Fool
The Global Pantry Reimagined: Unilever and McCormick Seal $65 Billion Merger Deal
April 09, 2026
In a move that has sent shockwaves through the global consumer staples market, Unilever (NYSE:UL) and McCormick & Company (NYSE:MKC) have officially entered into a definitive agreement to merge...
Via
MarketMinute
Topics
Economy
Supply Chain
The "Daily Pill" Revolution: Eli Lilly’s Orforglipron Shatters Records with 25% Weight Loss
April 08, 2026
In a watershed moment for the pharmaceutical industry, Eli Lilly and Company (NYSE: LLY) has officially crossed the threshold into a new era of metabolic medicine. Freshly released data from the...
Via
MarketMinute
Which of These Healthcare Stocks Is More Likely to Be a Millionaire Maker?
↗
April 08, 2026
One of these players is well-positioned for market leadership.
Via
The Motley Fool
3 Absurdly Cheap Dividend Stocks to Buy in April 2026
↗
April 08, 2026
These stocks offer high yields and trade at incredibly low earnings multiples.
Via
The Motley Fool
Topics
Economy
Lilly’s $47.8 Billion Bet: Why the Contessa Acquisition Redefines the Future of Medicine
April 06, 2026
In a move that has sent shockwaves through both the pharmaceutical and technology sectors, Eli Lilly and Company (NYSE: LLY) announced today, April 6, 2026, the finalized acquisition of Contessa, a...
Via
MarketMinute
Topics
Artificial Intelligence
Goldman Sachs Forecasts 12% S&P 500 Surge in 2026: The Five Pillars of a Maturing Bull Market
April 06, 2026
As the second quarter of 2026 kicks off, the investment landscape is being defined by a renewed sense of optimism from Wall Street’s most influential voices. Goldman Sachs (NYSE: GS) has officially...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Initial Public Offering
The "Liberation Day" Shockwave: US Finalizes 100% Tariffs on Branded Pharmaceutical Imports
April 06, 2026
In a move that has sent shockwaves through the global healthcare industry, the U.S. Administration officially finalized a sweeping new trade policy on April 6, 2026, imposing 100% tariffs on branded...
Via
MarketMinute
Topics
Economy
World Trade
Nuclear, Pharma & Travel Buybacks: Confident or Cautious Signals?
↗
April 06, 2026
Via
MarketBeat
Eli Lilly's One-Two Punch Could Knock Novo Nordisk Out of the Obesity Drug Fight
↗
April 04, 2026
The U.S. Food & Drug Administration just approved Eli Lilly's GLP-1 pill orforglipron.
Via
The Motley Fool
Earnings Revision Momentum: Why Analysts Upgraded S&P 500 Growth to 17%
April 03, 2026
As of April 3, 2026, the financial landscape is witnessing a historic disconnect between gritty macroeconomic headlines and exuberant corporate fundamentals. Despite a backdrop of stubborn...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Stocks
Why Novo Nordisk's Pricing Shift Could Unlock a Much Larger Obesity Market
↗
April 03, 2026
The drugmaker hasn't said its last word yet, as the weight-loss drug battle continues to heat up.
Via
The Motley Fool
The Great Metabolic Land Grab: Why Viking and Structure Have Become Big Pharma’s 'Irresistible' Targets
April 03, 2026
As of April 2026, the biotech landscape has undergone a seismic shift, moving from the "hype cycle" of early weight-loss treatments into an era of aggressive strategic consolidation. The market for...
Via
MarketMinute
Topics
Intellectual Property
Eli Lilly Secures Landmark FDA Approval for Oral Weight-Loss Pill, Sending Shares Soaring
April 02, 2026
Shares of Eli Lilly and Company (NYSE: LLY) surged 3.8% on Wednesday following the milestone FDA approval of Foundayo (orforglipron), the first once-daily oral weight-loss pill that does not require...
Via
MarketMinute
Topics
Economy
The Evolution of The Cigna Group: A Deep Dive into a Health Services Powerhouse (2026)
April 02, 2026
April 2, 2026 Introduction The Cigna Group (NYSE: CI) stands today at a pivotal crossroads, having undergone one of the most significant strategic transformations in the modern healthcare era. Long...
Via
Finterra
Topics
Artificial Intelligence
Economy
Lawsuit
The Trillion-Dollar Treatment: A Deep Dive into Eli Lilly and Company (LLY)
April 02, 2026
As of April 2, 2026, Eli Lilly and Company (NYSE:LLY) stands as the preeminent titan of the global healthcare sector. Historically recognized as a steady, century-old pharmaceutical giant, the company...
Via
Finterra
Topics
Artificial Intelligence
Economy
Intellectual Property
Why Eli Lilly Stock Trounced the Market Today
↗
April 01, 2026
Its first weight-loss pill was just approved by the FDA.
Via
The Motley Fool
Eli Lilly’s $47.8 Billion Masterstroke: The Contessa Acquisition and the New Era of Pharmaceutical Dominance
April 01, 2026
INDIANAPOLIS — In a move that has sent shockwaves through the global financial markets, Eli Lilly and Company (NYSE: LLY) announced early this morning, April 1, 2026, a definitive agreement to acquire...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Could This New Approval Be a Turning Point For Novo Nordisk?
↗
April 01, 2026
The pharmaceutical giant still has plenty of work to do to recover from recent woes.
Via
The Motley Fool
Is This Weight Loss Drug Stock a Buy After a New Approval?
↗
March 31, 2026
This little-known biotech company has a different strategy than the established weight-loss drug market leaders. But is it likely to be successful?
Via
The Motley Fool
The $1 Trillion Goliath: Why Eli Lilly’s $6.3B Centessa Bet Defines the Future of Neuroscience
March 31, 2026
Date: March 31, 2026 Introduction In the spring of 2026, the global pharmaceutical landscape is increasingly defined by the gravitational pull of a single entity: Eli Lilly and Company (NYSE: LLY)....
Via
Finterra
Topics
Economy
Intellectual Property
1 Reason This Biotech Stock Could Triple Before Year-End
↗
March 29, 2026
This little-known biotech could have a big hit on its hands with VK2735, a GLP-1 weight loss drug candidate.
Via
The Motley Fool
1 Reason Eli Lilly Stock Is Still a Buy
↗
March 28, 2026
Eli Lilly is much more than just a weight loss stock.
Via
The Motley Fool
Topics
Artificial Intelligence
Novo Nordisk: A Strong Contender in the Pharmaceutical Arena
↗
March 27, 2026
Could Novo Nordisk be the hidden gem you've been searching for? Join us as we evaluate its current market position and future prospects in this insightful episode.
Via
The Motley Fool
Eli Lilly Shares Slip Despite Positive Eczema Trial Results: Why the Market Reacted Coolly
March 27, 2026
INDIANAPOLIS – In a move that has left some retail investors scratching their heads, shares of Eli Lilly and Company (NYSE:LLY) have trended lower this week, despite the pharmaceutical giant releasing...
Via
MarketMinute
Eli Lilly vs Novo Nordisk: Which Obesity Drug Stock Is the Better Buy?
↗
March 27, 2026
It's not much of a contest right now.
Via
The Motley Fool
Could Buying Eli Lilly Today Set You Up for Life?
↗
March 26, 2026
Eli Lilly is leading the GLP-1 market, and investors are enthralled with the stock.
Via
The Motley Fool
Topics
Intellectual Property
What's Happening With Novo Nordisk Stock Today?
↗
March 26, 2026
Novo Nordisk A/S (NYSE:NVO) shares are moving higher on Thursday. Hims & Hers Health Inc (NYSE:HIMS) announced it will begin offering several of the Novo's FDA‑approved GLP‑1 medications, including the...
Via
Benzinga
Wave Life Sciences Shakes Biotech Sector with Breakthrough Obesity Data: A New Era for ‘Quality’ Weight Loss
March 26, 2026
The biotechnology landscape witnessed a defining moment on March 26, 2026, as Wave Life Sciences (Nasdaq: WVE) released highly anticipated interim Phase 1 data from its INLIGHT trial. The study, which...
Via
MarketMinute
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
